Literature DB >> 23304900

Suicidal ideation and self-harm following K2 use.

Shannon Thomas1, Sarah Bliss, Mohammed Malik.   

Abstract

INTRODUCTION: There is emerging evidence of adverse effects associated with K2 and similar synthetic cannabinoid compounds marketed as herbal alternatives to marijuana. Few studies were identified regarding the psychiatric effects of K2, including suicidal ideation, and to our knowledge none have been written related to self-harm following use of K2. CASE REPORT: A healthy 20-year-old single Caucasian male with no previous psychiatric diagnoses or treatment was brought by police to the ED with acute agitation, confusion, suicidal ideation, and self-inflicted trauma after smoking K2. Evaluation in the ED was notable for agitation, significant abrasions, respiratory rate of 30, negative UDS, and sinus tachycardia on EKG. Once medically stabilized, he was transferred to the inpatient psychiatric unit for continued monitoring. Upon evaluation on the psychiatric unit the following day, his symptoms had completely resolved, he continued to deny any previous psychiatric history, and was discharged home.
CONCLUSION: K2 and other synthetic cannabinoids have been shown to have significant medical and psychiatric adverse effects and they are still readily available for purchase. Evidence is limited regarding the psychiatric effects; however, synthetic cannabinoid products may potentially lead to suicidal ideation and self-harm behaviors amongst many other psychiatric symptoms.The long-term risks are still unclear, but some studies suggest the possibility of inducing chronic psychotic symptoms and worsening underlying psychiatric illness. Continued research is needed regarding the effects of these substances as well as an increase in public awareness of the risks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23304900

Source DB:  PubMed          Journal:  J Okla State Med Assoc        ISSN: 0030-1876


  12 in total

1.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

Review 2.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 3.  Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA, and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review.

Authors:  Elisabet Navarro-Tapia; Jana Codina; Víctor José Villanueva-Blasco; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Biology (Basel)       Date:  2022-05-23

4.  Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California.

Authors:  Karla D Wagner; Richard F Armenta; Alexis M Roth; Jane C Maxwell; Jazmine Cuevas-Mota; Richard S Garfein
Journal:  Drug Alcohol Depend       Date:  2014-05-27       Impact factor: 4.492

Review 5.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

Review 6.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Authors:  Cristina Miliano; Giovanni Serpelloni; Claudia Rimondo; Maddalena Mereu; Matteo Marti; Maria Antonietta De Luca
Journal:  Front Neurosci       Date:  2016-04-19       Impact factor: 4.677

7.  Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients.

Authors:  Merih Altintas; Leman Inanc; Gamze Akcay Oruc; Selim Arpacioglu; Huseyin Gulec
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-02       Impact factor: 2.570

8.  First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone.

Authors:  Aaron J Roberto; Aileen Lorenzo; Kevin J Li; Jonathan Young; Abhishek Mohan; Subhash Pinnaka; Kyle A B Lapidus
Journal:  Case Rep Psychiatry       Date:  2016-06-26

9.  A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus-A case report and review of the literature.

Authors:  Marc-Alain Babi; Christopher P Robinson; Carolina B Maciel
Journal:  SAGE Open Med Case Rep       Date:  2017-12-05

Review 10.  Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.

Authors:  Aviv M Weinstein; Paola Rosca; Liana Fattore; Edythe D London
Journal:  Front Psychiatry       Date:  2017-08-23       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.